Key facts
- Notable investors include Hangzhou Hi-Tech Financial Investment Group, Hangzhou Industrial Investment Group, Hangzhou Zhengjing Private Equity Fund Management.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for AB-RayBio
- ·The full record, as it builds
Funding rounds
No funding rounds for AB-RayBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About AB-RayBio
Manufacturer of targeted radiopharmaceutical devices designed for therapeutic and diagnostic purposes. The company integrates small molecule discovery, AI-driven peptide screening, radiolabeling, non-clinical evaluation, and rapid clinical translation capabilities, enabling oncology researchers and clinicians to access precision-targeted solutions for unmet clinical needs in cancer treatment and diagnosis.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2024
- Website
- abraybio.com/
- Ownership
- Privately Held (backing)
AB-RayBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AB-RayBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AB-RayBio in its N-PORT filings yet. We sweep new filings monthly.